• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

Diabetes and Mentall Illness: 3 New Studies

Slideshow

Results include: The metabolic dangers of neuroleptic Rx in youth; prevalence of T2DM in minorities with severe mental illness; and gaps in care for mentally ill with T2DM.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
Oral Semaglutide Wins FDA Approval to Reduce Risk of MACE in Adults with T2D at High Risk

Oral Semaglutide Wins Approval to Reduce Risk of MACE in Adults with T2D at High Risk

Grace Halsey
October 20th 2025
Article

The first FDA-approved oral GLP-1 receptor agonist received an expanded indication for both primary and secondary prevention in T2D patients at elevated CV risk.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Three GLP-1 Receptor Agonists Show Comparable Cardiorenal Protection in Large US Cohort with T2D / image credit ©Gecko Studio/stock.adobe.com

Three GLP-1 Receptor Agonists Show Comparable Cardiorenal Protection in Large US Cohort with T2D

Grace Halsey
October 15th 2025
Article

GLP-1 RAs liraglutide, semaglutide, and dulaglutide showed similar kidney and cardiovascular outcomes more than 20,000 US veterans with type 2 diabetes.

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Sydney Jennings
July 22nd 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

FDA Accepts MannKind sBLA for Inhaled Insulin for Children and Adolescents

FDA Accepts MannKind sBLA for Inhaled Insulin for Children and Adolescents with Diabetes

Grace Halsey
October 13th 2025
Article

The sBLA includes data from the phase 3 INHALE-1 study, which showed Afrezza noninferior to MDI insulin. A PDUFA date is set for May 29, 2026.

Approximately Half of People with Diabetes Worldwide Unaware They Have the Disease: Daily Dose / Image credit: ©New Africa/AdobeStock

Approximately Half of People with Diabetes Worldwide Unaware They Have the Disease: Daily Dose

Sydney Jennings
September 30th 2025
Article

Your daily dose of the clinical news you may have missed.

© 2025 MJH Life Sciences

All rights reserved.